Market Overview

UPDATE: Morgan Stanley Downgrades Neurocrine Biosciences on Recent Stock Appreciation

Related NBIX
AbbVie Offers Plans to Proceed to Phase 3 Evaluation of Elagolix
Biotech Expert Talks Potential M&A Activity, Partnerships And Women's Health

In a report published Wednesday, Morgan Stanley analyst David Friedman downgraded Neurocrine Biosciences (NASDAQ: NBIX) to EqualWeight from OverWeight, raising its price target to $16.00.

According to the report, the price target increase is based on a set of model changes including adding VMAT sales. The downgrade is due to the recent stock appreciation.

“While we expect clinical and commercial success for Elagolix in both endometriosis and uterine fibroids, we are changing our rating from OW to EW based on a seemingly more balanced risk-reward with the stock at current levels,” the report noted. “We have made a series of model changes, including adding '854 (VMAT) sales to our model in light of the recent, albeit somewhat modest benefit shown in the KINECT 2.”

NBIX closed Tuesday at $18.51 with shares trading up 89.69 percent.

Latest Ratings for NBIX

Jul 2015Leerink SwannAssumesOutperform
Jun 2015Piper JaffrayMaintainsOverweight
Mar 2015JP MorganInitiates Coverage onOverweight

View More Analyst Ratings for NBIX
View the Latest Analyst Ratings

Posted-In: David Friedman Morgan StanleyAnalyst Color Downgrades Analyst Ratings


Related Articles (NBIX)

View Comments and Join the Discussion!

Get Benzinga's Newsletters